Current Pharmaceutical Interventions and Drug Design in the Management of Diabetes and Diabetic Complications

Author(s): Gopal L. Khatik, Ashok K. Datusalia, Manish Vyas

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 23 , 2019


Become EABM
Become Reviewer
Call for Editor

[1]
Usman B, Satija S, Sharma N, et al. Recent developments in alpha-glucosidase inhibitors for management of type-2 diabetes: An update. Curr Pharm Des 2019; 25(23): 2510-25.
[2]
Prabhakar PK, Sivakumar PM. Protein tyrosine phosphatase 1B inhibitors: A novel therapeutic strategy for the management of type 2 diabetes mellitus. Curr Pharm Des 2019; 25(23): 2526-39.
[3]
Ahsan W. The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: A current perspective. Curr Pharm Des 2019; 25(23): 2540-54.
[4]
Taliyan R, Sarathlal KC, Kakoty V. Therapeutic approaches to Alzheimer’s type of dementia: A focus on FGF21 mediated neuroprotection. Curr Pharm Des 2019; 25(23): 2555-68.
[5]
Mishra V, Yadav N, Saraogi GK, Tambuwala MM, Giri N. Dendrimer based nanoarchitectures in diabetes management: An overview. Curr Pharm Des 2019; 25(23): 2569-83.
[6]
Kalvala AK, Khan I, Gundu C, Kumar A. An overview on ATP dependent and independent proteases including an anterograde to retrograde control on mitochondrial function: Focus on diabetes and diabetic complications. Curr Pharm Des 2019; 25(23): 2584-94.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 23
Year: 2019
Published on: 30 September, 2019
Page: [2509 - 2509]
Pages: 1
DOI: 10.2174/138161282523190913113841

Article Metrics

PDF: 30
HTML: 4
EPUB: 1